[1]沈建东,戴 锋,王 斌,等.磷脂酰肌醇-4，5-二磷酸肌醇-3-激酶对原发性肝癌TACE治疗反应的预测作用[J].介入放射学杂志,2024,33(04):382-385.
　SHEN Jiandong,DAI Feng,WANG Bin,et al.The application of PIK3CA in predicting the efficacy of TACE in the treatment of primary liver cancer[J].journal interventional radiology,2024,33(04):382-385.
点击复制

磷脂酰肌醇-4，5-二磷酸肌醇-3-激酶对原发性肝癌TACE治疗反应的预测作用()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年04
页码:
382-385
栏目:
肿瘤介入
出版日期:
2024-05-04

文章信息/Info

Title:
The application of PIK3CA in predicting the efficacy of TACE in the treatment of primary liver cancer
作者:
沈建东;  戴 锋;  王 斌;  王晓维;  丁 苇;  殷梦杰;  蒋逢辰;  付守忠
Author(s):
SHEN Jiandong;  DAI Feng;  WANG Bin;  WANG Xiaowei;  DING Wei;  YIN Mengjie;  JIANG Fengchen;  FU Shouzhong.
Department of Vascular Intervention， Nantong Municipal No.3 People’s Hospital， Nantong， Jiangsu Province 226001， China
关键词:
【关键词】 肝细胞肝癌;  经导管动脉化疗栓塞术;  磷脂酰肌醇-4; 5-二磷酸肌醇-3-激酶
文献标志码:
A
摘要:
【摘要】 目的 探讨经导管动脉化疗栓塞术（TACE）治疗的原发性肝癌患者磷脂酰肌醇-4，5-二磷酸肌醇-3-激酶（PIK3CA）的表达及其与TACE治疗反应的相关性。方法 从TCGA数据库下载425例肝癌患者PIK3CA的表达量。利用GSE104580数据集内TACE治疗敏感和不敏感患者癌组织PIK3CA表达量，分析两组基因表达差异，绘制ROC曲线分析TACE治疗敏感性与PIK3CA表达的相关性。从GSE14520数据集下载具有完整临床资料、接受TACE治疗的肝细胞癌27例，基于PIK3CA的表达量最佳截断值，分成PIK3CA高表达组和PIK3CA低表达组，比较两组患者的临床资料。应用“survminer”R包进行Kaplan-Meier生存分析。结果 肝癌组织PIK3CA表达明显高于癌旁组织；TACE不敏感患者癌组织PIK3CA表达量高于TACE敏感患者，TACE治疗敏感性与PIK3CA表达相关性的ROC曲线下面积（AUC）为0.645；生存分析显示PIK3CA表达量越低，患者生存时间越长，且1、2、3年的AUC分别为0.765、0.713、0.633。结论 PIK3CA对于肝细胞癌有一定的诊断价值，有可能作为TACE治疗敏感性的预测指标。

参考文献/References:

［1］ Hoxhaj G， Manning BD. The PI3K- AKT network at the interface of oncogenic signalling and cancer metabolism［J］. Nat Rev Cancer， 2020， 20： 74- 88.
［2］ Candia J， Bayarsaikhan E， Tandon M， et al. The genomic landscape of Mongolian hepatocellular carcinoma［J］. Nat Commun， 2020， 11： 4383.
［3］ Wang C， Che L， Hu J， et al. Activated mutant forms of PIK3CA cooperate with RasV12 or c- Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade［J］. Liver Int， 2016， 36： 1176- 1186.
［4］ Goncalves MD， Hopkins BD， Cantley LC. Phosphatidylinositol 3- kinase， growth disorders， and cancer［J］. N Engl J Med， 2018， 379： 2052- 2062.
［5］ Andre F， Ciruelos E， Rubovszky G， et al. Alpelisib for PIK3CA- mutated， hormone receptor- positive advanced breast cancer［J］. N Engl J Med， 2019， 380： 1929- 1940.
［6］ Xu H， Chen K， Shang R， et al. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma［J］. Cell Death Dis， 2021， 12： 920.
［7］ 张司马康，施海彬，周春高， 等. 中性粒细胞和淋巴细胞比值对原发性肝癌肝动脉化疗栓塞术后的预测价值［J］． 介入放射学杂志， 2022， 31：697- 701．
［8］ 徐永康，付舒敏，李 丹，等． 肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展［J］． 介入放射学杂志， 2023， 32：94- 97．

相似文献/References:

[1]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(04):621.
[2]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(04):78.
[3]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(04):805.
[4]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(04):406.
[5]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(04):449.
[6]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(04):435.
[7]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(04):1114.
[8]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
　WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus： a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(04):419.
[9]李 征,米登海,杨克虎,等.经动脉化疗栓塞联合微波消融治疗肝癌有效性和安全性的系统评价[J].介入放射学杂志,2015,(11):957.
　LI Zheng,MI Deng- hai,YANG Ke- hu,et al.Effectiveness and safety of TACE combined with MWA for primary hepatic cancer： a systematic review[J].journal interventional radiology,2015,(04):957.
[10]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(04):332.
[11]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(04):381.
[12]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(04):1052.
[13]余晨曦,滕皋军.经导管动脉化疗栓塞术抵抗研究进展 [J].介入放射学杂志,2017,(12):1063.
　YU Chenxi,TENG Gaojun.Transarterial chemoembolization refractory： current research progress[J].journal interventional radiology,2017,(04):1063.
[14]徐 圣,张学军,石宝琪,等.微波消融联合经导管动脉化疗栓塞术治疗肝细胞癌生存预测[J].介入放射学杂志,2020,29(05):508.
　XU Sheng,ZHANG Xuejun,SHI Baoqi,et al.The survival prediction for HCC patients receiving microwave ablation combined with TACE[J].journal interventional radiology,2020,29(04):508.
[15]荆 霞,徐 圣.Callispheres栓塞后综合征的综合护理模式与常规护理模式比较[J].介入放射学杂志,2020,29(07):722.
　JING Xia,XU Sheng..Comprehensive nursing mode versus routine nursing mode for post- embolization syndrome in HCC patients after DEB- TACE： a comparative study[J].journal interventional radiology,2020,29(04):722.

备注/Memo

备注/Memo:
（收稿日期：2023- 04- 24）
（本文编辑：新 宇）
更新日期/Last Update: 2024-05-04